Skip to main content
. 2020 Nov 9;80(3):339–348. doi: 10.1136/annrheumdis-2020-218599

Figure 3.

Figure 3

Adjusted mean change over time from baseline to day 365 in circulating T-cell subtypes: (A) CD4 TEM, (B) Th1, (C) Treg, (D) Tfh and (E) ICOS+ Tfh cells. Adjusted mean differences at day 365 are versus the placebo arm switched to abatacept (rather than vs placebo). (A) CD4+TEM expressed as a percentage of CD4+ cells. Markers for CD4 TEM cells=CD3+CD4+CD45RA–CCR7–. (B) Markers for Th1 cells=CD3+CD4+CXCR3+CCR6–. (C) Treg expressed as a percentage of CD4 T cells. Markers for Treg cells=CD3+CD4+CD25+CD127–/LO. (D) Tfh is expressed as a percentage of CD4 +T cells (CXCR5+PD1+). Markers for Tfh cells=CD3+CD4+CD185+CD279+. (E) ICOS+ Tfh expressed as a percentage of Tfh cells. Markers for ICOS+ Tfh cells=CD3+CD4+CD185+CD279+CD278+. ICOS+ Tfh, ICOS-positive Tfh costimulator; TEM, effector memory T cells; Tfh, T follicular helper cells; Th1, T helper type 1 cells; Treg, regulatory T cells.